Immunotherapy in Advanced Non-Small Cell Lung Cancer: About Two Case Reports Imunoterapia no Cancro do Pulmão de Não Pequenas Células Doença Avançada: A Propósito de Dois Casos Clínicos

Main Article Content

Raquel Fontes
Bárbara Parente - Corresponding Author

Estrada da Circunvalação 14341, 4100-180 Porto, Portugal

Maria Manuel Lopes
Carolina Monteiro

Abstract

In light of current knowledge, the treatment with immunotherapy in advanced non-small cell lung cancer disease presents thebest results in patients with programmed death ligand 1 (PD-L1) + expression. We present two different clinical cases, both successful: the first refers to a 91-year-old male patient with 90% PD-L1 expression and high response rate to the treatment of immunotherapy with pembrolizumab at a dose of 200 mg every 3 weeks; in the second case, a 47-year-old female with PD-L1 negative expression and in whom immunotherapy was used as second line after progression under chemotherapy treatment and who also had a complete response with the use of atezolizumab at the dose of 1200 mg every 3 weeks.

Keywords: Atezolizumab; Carcinoma, Non-Small Cell Lung/therapy; Immunotherapy; Pembrolizumab; Programmed Cell Death 1 Receptor

Article Details

1.
Fontes R, Parente B, Lopes MM, Monteiro C. Immunotherapy in Advanced Non-Small Cell Lung Cancer: About Two Case Reports: Imunoterapia no Cancro do Pulmão de Não Pequenas Células Doença Avançada: A Propósito de Dois Casos Clínicos. Gaz Med [Internet]. 2019 Mar. 31 [cited 2021 Dec. 3];6(1). Available from: https://www.gazetamedica.pt/index.php/gazeta/article/view/236
Section
CLINICAL CASE